NKGen Biotech, Inc. (OTC: NKGN) ('NKGen” or the 'Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural ...

CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 17, Morgan Stanley increased its price target on CRISPR Therapeutics AG ...

Analysts expect Legend to post earnings of 1 cent per share on revenue of $310.7 million, representing a sequential improvement from the third quarter’s loss of 11 cents per share on $272.3 million in ...

Scientists Meet in Valencia to Define the Path to Clinical Integration Valencia, Spain. June 9–10, 2026 Researchers, clinicians, and biotechnology innovators from around the world will gather in ...

Building an AI infrastructure for biotech. Bacteria that munch on cancer. How to best make a cold brew. All that and more in ...

PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives ...

COPENHAGEN, Feb 24 () - Novo Nordisk said on Tuesday its ‌triple agonist UBT251 of ‌the receptors for GLP-1, GIP and glucagon ...

O]ur companies have until June of 2028 to get there. That should not be a sigh of relief. That should be a, oh my gosh, we've got a lot of work," said Major.

Recursion Pharmaceuticals crashed 90% but JPMorgan upgraded with $11 target implying near tripling. Eli Lilly partnered with Nvidia on a $1B AI drug discovery collaboration using Vera Rubin chips.

The typical biotech playbook is straightforward but risky: Raise large amounts of capital with an initial public offering, burn cash while navigating clinical trials, then submit a new drug ...

Tell us about your career journey as the co-founder of differen | Barbara Wirostko, MD, CMO & Co-Founder of Qlaris Bio, and Co-Founder of MyEyes, discusses her career journey founding biotech and ...

RBC Capital Markets believes that recent January data on Biohaven's epilepsy drug has helped reduced uncertainty around the treatment. The bank upgraded the biopharmaceutical stock to outperform from ...